Foghorn Therapeutics' revenue estimates downgraded by analys...

Moomoo AI Mar 10, 2024 21:40

Foghorn Therapeutics' revenue estimates downgraded by analysts, expected losses per share increased. The company's slower growth compared to industry peers could be a concern for shareholders.

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Analysts Just Slashed This Year's Estimates

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

5117 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4712Followers

0Following

10KVisitors